Price Reductions for Third Transitional Cycle
Summary of 1 August 2012 Price Reductions for Third Transitional Cycle by Drug / Manner of Administration / Weighted Average Percentage Reduction.
|
Drug |
Manner of Administration |
Weighted Average Percentage Reduction |
|---|---|---|
|
Amisulpride |
Oral |
18.27% |
|
Bisoprolol |
Oral |
18.75% |
|
Cefalotin |
Injection |
16.99% |
|
Doxorubicin |
Injection/intravesical |
32.97% |
|
Escitalopram |
Oral |
36.76% |
|
Levetiracetam |
Oral |
14.15% |
|
Meloxicam |
Oral |
23.62% |
|
Mitozantrone |
Injection |
18.25% |
|
Ondansetron |
Injection |
77.25% |
|
Oxaliplatin |
Injection |
51.76% |
|
Oxybutynin |
Oral |
11.25% |
|
Perindopril with Indapamide |
Oral |
11.59% |
|
Prochlorperazine |
Oral |
25.55% |
For further information about specific prices for pharmaceutical items please see the Federal Register of Legislative Instruments (FRLI): www.comlaw.gov.au/Details/F2012L00931
